作者：宋秀英1 ，韩嘉明1 ，马玉兰2

单位：

1.810000青海省西宁市，青海大学　2.810012青海省西宁市，青海省高原医学科学研究院 青海省心脑血管病专科医院老年科

单位（英文）：

1.Qinghai University, Xining 810000, China 2.Department of Geriatrics, Qinghai Cardio-Cerebrovascular Specialty Hospital/Qinghai High Altitude Medical Research Institute, Xining 810012, China

关键词：

心血管疾病；动脉粥样硬化性心血管疾病；心力衰竭；心房颤动；达格列净；综述

关键词（英文）：

Cardiovascular diseases; Atherosclerotic cardiovascular disease; Heart failure; Atrial fibrillation; Dapagliflozin; Review

中图分类号：

R 54

DOI：

10.12114/j.issn.1008-5971.2024.00.113

基金项目：

国家自然科学基金地区科学基金项目（81760084）

摘要：

目前，动脉粥样硬化性心血管疾病（ASCVD）、心力衰竭（HF）、心房颤动（AF）等心血管疾病 尚无治愈方法，只能通过药物长期治疗来延缓病情进展，患者发病率及病死率较高。钠-葡萄糖协同转运蛋白2抑制 剂——达格列净为一种相对较新的口服降糖药物，目前研究较为广泛，但部分研究发现，无论患者是否合并糖尿病， 达格列净均可以降低心血管疾病患者的心血管死亡率或因HF住院率，因而其在心血管疾病治疗中也可发挥重要作用。 本文综述了达格列净治疗ASCVD、HF、AF的效果及机制，以期为心血管疾病的预防及治疗提供新思路。

英文摘要：

At present, there is no cure for atherosclerotic cardiovascular disease (ASCVD) , heart failure (HF) , atrial fibrillation (AF) and other cardiovascular diseases, which can only be delayed by long-term drug treatment, and the morbidity and mortality of patients are relatively high. The sodium-glucose cotransporter 2 inhibitor, dapagliflozin, is a relatively new oral hypoglycemic drug, which has been widely studied. However, some studies have found that dapagliflozin can reduce the cardiovascular mortality or hospitalization rate due to HF in patients with cardiovascular disease regardless of whether the patients are complicated with diabetes, so it can also play an important role in the treatment of cardiovascular disease. This article reviewed the effect and mechanism of dapagliflozin in the treatment of ASCVD, HF and AF, in order to provide new ideas for the prevention and treatment of cardiovascular diseases.

参考文献：